Oral therapy sees a new hopeful for immune diseases in Dice’s DC-806 

Positive psoriasis data from Dice suggest the biotech’s oral small molecule against IL-17 could further intensify the competition in the already crowded market for immune disorder therapies.

Dice Therapeutics Inc. (NASDAQ:DICE) gained $15.35 (62%) to $40 on the early-stage readout, adding $587 million in market cap to end Tuesday’s trading session with a valuation of $1.5 billion. The move returns the stock to a level it’s not seen since Dice’s initial months of trading last fall, when it debuted among 2021’s crop of preclinical IPOs. ...